PT - JOURNAL ARTICLE AU - Xin Zhang AU - Xun Zhang AU - Xi Chen AU - Yuehua Liu AU - Xintong Zhao TI - The Morbidity Costs of Air Pollution through the Lens of Health Spending in China AID - 10.1101/2021.09.11.21256274 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.11.21256274 4099 - http://medrxiv.org/content/early/2021/09/15/2021.09.11.21256274.short 4100 - http://medrxiv.org/content/early/2021/09/15/2021.09.11.21256274.full AB - This study offers one of the first causal evidence on the morbidity costs of fine particulates (PM2.5) for all age cohorts in a developing country, using individual-level healthcare spending data from the basic medical insurance program in Wuhan, China. Our instrumental variable (IV) approach uses thermal inversion to address potential endogeneity in PM2.5 concentrations and shows that PM2.5 imposes a significant impact on medical expenditures. The IV estimate suggests that a 10 μg/m3 reduction in monthly average PM2.5 leads to a 2.79% decrease in the value of health spending and a 0.70% decline in the number of transactions in pharmacies and health facilities. The effect is more salient for males, children, and older adults. Moreover, our estimates provide a lower bound of people’s willingness-to-pay, which amounts to CNY 51.85 (or USD 8.38) per capita per year for a 10 μg/m3 reduction in PM2.5.JEL Codes Q51, Q53, I11, I31Conflict of interest The authors declare that they have no conflict of interest.Competing Interest StatementThe authors have declared no competing interest.Funding StatementXin Zhang acknowledges financial support from the National Natural Science Foundation of China (72003014). Xun Zhang thanks the National Natural Science Foundation of China (71973014) for financial support. Xi Chen is grateful for financial support from the James Tobin Research Fund at Yale Economics Department, Yale Macmillan Center Faculty Research Award (2019), the U.S. PEPPER Center Scholar Award (P30AG021342), NIH/NIA Career Development Award (K01AG053408).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by the local ethics committee of the Beijing Normal University School of Statistics. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResearchers may apply and register for accessing a random representative sample of health spending data via the official webpage of the Wuhan Healthcare Security Administration. http://ybj.wuhan.gov.cn/